GT Medical Technologies is a medical device company dedicated to improving the lives of patients with brain tumors.
GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds.
GT Medical Technologies was founded in 2017 by David G. Brachman, Emad Youssef, Heyoung McBride, Peter Nakaji, Theresa Thomas. The company is headquartered in Tempe, Arizona.
GT's first product, GammaTile™, is a Surgically Targeted Radiation Therapy (STaRT) that treats patients with newly diagnosed malignant and recurrent brain tumors. GammaTile™ is protected by 10 US and 2 Canadian issued patents, and 1 EPO patent.
GammaTile Therapy delivers immediate, targeted radiation helping to eradicate brain tumor cells before they can replicate post-surgery. GammaTiles are bioresorbable collagen tiles embedded with radiation sources.
GammaTile has treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 80 hospitals, with more centers being added each month.
GT Medical is backed by MVM Partners, Gilde Healthcare Partners, MedTech Venture Partners, BlueStone Venture Partners, and others. The company raised $45M in a Series C round on Mar 23, 2023. This brings GT Medical's total funding to $74M to date.